Monte Rosa Therapeutics IncGLUE
Price$11.26Intrinsic value$6.7041% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $28.7M-62.0% YoYTTM through 30 Jun 2026
Net Income -$161.1MTTM through 30 Jun 2026
Free Cash Flow -$32.1MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-595.6%
Operating Margin-1,188.5%
Net Margin-560.8%

Returns

-32.6%ROE
-6.0%ROA

Balance Sheet Health

Debt / Equity0.07x
Current Ratio9.54x
Net Debt-$666.2Mnet cash position
Cash & Equivalents$90.1M

Quality Metrics

Altman Z-Score2.18
Piotroski F-Score2 / 9
FCF Margin-111.7%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $123.7M
Diluted EPS
'21'22'23'24'25
FY2025: $-0.47

Dividend

No dividend

Capital Allocation

Capex Intensity27.9%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.